The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Songfeng ChenDeliang LiuHonghui ChenAijun LiaoFangfang LiChengxia LiuXing LiShengbao LiYan ZhangYang WangMin XiaQinghong GuoXinpu MiaoZhili WenMin XuHekun YinHuixin ChenMinhu ChenYing Lian XiaoPublished in: Alimentary pharmacology & therapeutics (2022)
This study demonstrated the non-inferior efficacy of keverprazan to lansoprazole in treating EO. The incidences of drug-related AEs were comparable between keverprazan and lansoprazole.